Bioactive small-molecule inhibitors represent a treasure chest for future drugs. In vitro high-throughput screening is a common approach to identify the small-molecule inhibitors that bind tightly to purified targets. Here, we investigate the inhibitor-target binding/unbinding kinetics in E. coli cells using a benzimidazole-derivative DNA inhibitor as a model system. We find that its unbinding rate is not constant but depends on cell growth rate. This dependence is mediated by the cellular activity, forming a feedback loop with the inhibitor's activity. In accordance with this feedback, we find cell-to-cell heterogeneity in inhibitor-target interaction, leading to co-existence of two distinct subpopulations: actively growing cells that dissociate the inhibitors from the targets and non-growing cells that do not. We find similar heterogeneity for other clinical DNA inhibitors. Our studies reveal a mechanism that couples inhibitor-target kinetics to cell physiology and demonstrate the significant effect of this coupling on drug efficacy.
Keyphrases
- small molecule
- induced apoptosis
- single cell
- escherichia coli
- cell cycle arrest
- stem cells
- cell therapy
- signaling pathway
- cell proliferation
- cystic fibrosis
- mesenchymal stem cells
- single molecule
- pseudomonas aeruginosa
- molecular docking
- current status
- bone marrow
- tissue engineering
- electronic health record
- klebsiella pneumoniae
- intimate partner violence
- adverse drug